Idexx Laboratories (IDXX) FY2025 10-K Annual Report
Idexx Laboratories (IDXX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 20, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Idexx Laboratories FY2025 10-K Analysis
Business Overview
- • Core business model: Provider of veterinary diagnostics, software, services, and water testing solutions with recurring consumable sales and instrument placements
- • New product emphasis: Launch and sales growth of IDEXX inVue Dx Analyzer driving 51.8% increase in instrument revenue for Companion Animal Group
- • Strategic shift: Increased focus on expanding SaaS veterinary software services and diagnostic imaging systems, with 10.6% revenue growth in these areas
- • Quantitative highlight: Total company revenue $4.3B, up 10.4% YoY with organic revenue growth of 9.6%; operating income up 20.5% to $1.36B
- • Noteworthy fact: Significant reduction in general & administrative expenses due to settled $61.5M litigation accrual, boosting net operating income and margins
Management Discussion & Analysis
- • Revenue $3.52B, up 9% YoY from $3.23B in prior year driven by Companion Animal Group growth
- • Operating margin 25.3% vs 24.1% prior year reflecting scale and efficiency gains
- • Best segment Companion Animal Group revenue $2.75B, up 11% YoY; worst segment Water revenue $309M, down 4% YoY
- • Operating cash flow $850M; capital expenditures $120M; share repurchases $200M; dividends paid $75M
- • Management expects mid-single-digit revenue growth and stable operating margin in FY2027; risks include supply chain disruptions and regulatory impacts
Risk Factors
- • Tariff risk from changing U.S. and retaliatory tariffs increasing production costs and reducing profit margins on 36% of revenue from international sales
- • Global sales exposure with 36% revenue from over 175 countries vulnerable to adverse trade policy shifts
- • Supply dependency on third-party suppliers in U.S., Europe, and Asia Pacific for key components and raw materials
- • Sales volatility risk from distributor inventory fluctuations affecting reported sales growth, with limited visibility in certain countries
- • No disclosed specific financial leverage or key-person risks detailed in the section provided
Idexx Laboratories FY2025 Key Financial MetricsXBRL
Revenue
$4.3B
▲ +10.4% YoY
Net Income
$1.1B
▲ +19.3% YoY
Gross Margin
61.8%
▲ +76bp YoY
Operating Margin
31.6%
▲ +265bp YoY
Net Margin
24.6%
▲ +184bp YoY
ROE
66.0%
▲ +1034bp YoY
Total Assets
$3.4B
▲ +1.7% YoY
EPS (Diluted)
$13.08
▲ +22.6% YoY
Operating Cash Flow
$1.2B
▲ +27.2% YoY
Source: XBRL data from Idexx Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Idexx Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.